R-Farm Novosyolki

History

2022: Attraction of 800 million rubles from FRP

In July 2022, the expert council of the Industrial Development Fund (FRP) approved 12 loans for the implementation of projects in various regions of the country in the amount of more than 5.33 billion rubles. Among them is the project of the R-Pharm group.

The Pharmaceutical Plant "R-Pharm Novosyolki" with the help of a loan from the FRP in the amount of 802 million rubles organizes the production of 17 medical products from the list of vital and essential drugs (VED) in Yaroslavl. Among them are antiviral, antidiabetic, anticoagulants, agents for the treatment of cardiovascular diseases and the correction of neurological disorders.

R-Pharm raised 800 million rubles to increase production

The production capacity will be 7 million packages per year. Within the framework of the project, 21 workplaces will be created. The total project budget is 1.18 billion rubles, of which 802 million rubles can be provided to the FRP in the form of a preferential loan.

It is assumed that the project will contribute to the achievement of the objectives of the national goal "Preservation of the population, health and well-being of people" and the implementation of the national project "Health."

According to representatives of R-Pharm Novosyolki, by July 2022, more than half (54%) of the Russian drug market from the VED list is occupied by foreign drugs, the expansion of production in Yaroslavl is aimed at reducing the share of imports.^[1]

In July 2022, R-Farm International, which develops assets for the production and distribution of foreign medical equipment, changed owners. In particular, 33% of the shares now belong to the general director of R-Pharm Vasily Ignatiev, 1% to the general director of R-Pharm Ventures Andrei Smirnov. Experts attribute this to an attempt to secure assets from sanctions.

Notes

Шаблон:Remarks